Who is sponsoring NCT00655616?

NCT00655616 is sponsored by University of Dundee.

What drugs are being tested in NCT00655616?

Interventions: Montelukast Placebo, Salmeterol, Montelukast.

What is the status of NCT00655616?

NCT00655616 is currently COMPLETED.

Last reviewed 2011-03-23 · How we verify

A Proof-of-concept Study to Evaluate the Benefit From add-on Therapy With Montelukast Versus Salmeterol in Children With Asthma Carrying the Arg/Arg-16 beta2-receptor Genotype

NCT00655616 NA COMPLETED

The purpose of this study is to determine whether patients with asthma who carry a genotype associated with adverse outcomes with long-acting beta-2 agonists like salmeterol show greater benefit from the use of an asthma drug that works via alternative pathways like montelukast.

Details

Lead sponsor	University of Dundee
Phase	NA
Status	COMPLETED
Enrolment	64
Start date	2007-08
Completion	2009-12

Conditions

Asthma

Interventions

Montelukast Placebo
Salmeterol, Montelukast

Primary outcomes

Oral montelukast is associated with reduced school absences in comparison to inhaled salmeterol over a period of 1 year in Arg/Arg-16 asthmatic children — Every 3 months

Countries

United Kingdom